(Q37931887)

25 August 2017

1 reference

title

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis (English)

1 reference

25 August 2017

David Neal Franz

1

1 reference

25 August 2017

publication date

1 August 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

1181-1192

1 reference

The tuberous sclerosis complex

25 August 2017

cites work

1 reference

Hereditary neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

Tuberous sclerosis complex and epilepsy: recent developments and future challenges

21 January 2018

1 reference

The pathogenesis and imaging of the tuberous sclerosis complex

21 January 2018

1 reference

The tuberous sclerosis complex

21 January 2018

1 reference

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

Genetics and molecular biology of tuberous sclerosis complex

21 January 2018

1 reference

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways

21 January 2018

1 reference

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

Tuberous sclerosis complex proteins control axon formation

21 January 2018

1 reference

The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment

21 January 2018

1 reference

Diffusion features of white matter in tuberous sclerosis with tractography

21 January 2018

1 reference

A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival

21 January 2018

1 reference

Recent advances in neurobiology of Tuberous Sclerosis Complex.

21 January 2018

1 reference

Role of mTOR in physiology and pathology of the nervous system

21 January 2018

1 reference

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

21 January 2018

1 reference

Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation

21 January 2018

1 reference

Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

21 January 2018

1 reference

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

PEComas: the past, the present and the future

21 January 2018

1 reference

Behavior problems in children with tuberous sclerosis complex and parental stress.

21 January 2018

1 reference

Subependymal giant cell tumors in tuberous sclerosis complex

21 January 2018

1 reference

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

21 January 2018

1 reference

Current trends in the treatment of infantile spasms

21 January 2018

1 reference

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis

21 January 2018

1 reference

Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex

21 January 2018

1 reference

Cognitive prognosis of patients with tuberous sclerosis complex.

21 January 2018

1 reference

Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated

21 January 2018

1 reference

Lymphangioleiomyomatosis: a clinical update.

21 January 2018

1 reference

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment

21 January 2018

1 reference

Perinatal (fetal and neonatal) tuberous sclerosis: a review

21 January 2018

1 reference

Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis

21 January 2018

1 reference

Therapeutic targeting of mTOR in tuberous sclerosis

21 January 2018

1 reference

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies

21 January 2018

1 reference

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

Management of epilepsy in tuberous sclerosis complex.

21 January 2018

1 reference

Current management of tuberous sclerosis complex

21 January 2018

1 reference

Tuberous sclerosis complex: a brave new world?

21 January 2018

1 reference

Cardiac rhabdomyoma in tuberous sclerosis: hyperactive Erk signaling

21 January 2018

1 reference

Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.

21 January 2018

1 reference

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

21 January 2018

1 reference

Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex

21 January 2018

1 reference

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

21 January 2018

1 reference

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

21 January 2018

1 reference

Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex

21 January 2018

1 reference

Sirolimus and tuberous sclerosis-associated renal angiomyolipomas

21 January 2018

1 reference

Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.

21 January 2018

1 reference

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

21 January 2018

1 reference

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex

21 January 2018

1 reference

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis

21 January 2018

1 reference

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain

21 January 2018

1 reference

The evolving experience using everolimus in clinical transplantation

21 January 2018

1 reference

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

Rapamycin: something old, something new, sometimes borrowed and now renewed

21 January 2018

1 reference

Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.

21 January 2018

1 reference

21 January 2018

1 reference

Cancer drugs to treat birth defects

21 January 2018

1 reference

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

21 January 2018

1 reference

Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade

21 January 2018

1 reference

New roles for Notch in tuberous sclerosis

21 January 2018

1 reference

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

21 January 2018

1 reference

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.93

1 reference

25 August 2017

1 reference